| |
 |
|
|
|
|
|
|
|
|
|
| |
|
Notes |
|
2009
R million
(Unaudited)
|
|
|
2008
R million
(Unaudited)
|
|
Year ended
30 Sept
2008
R million
(Audited)
|
| |
Share capital and premium |
|
|
|
|
|
|
|
|
| |
Balance at the beginning of the period |
|
|
106,9 |
|
|
90,8 |
|
90,8 |
| |
Issue of shares |
|
|
3,1 |
|
|
1,2 |
|
16,1 |
| |
Balance at the end of the period |
|
|
110,0 |
|
|
92,0 |
|
106,9 |
| |
Share-based payment reserve |
|
|
|
|
|
|
|
|
| |
Balance at the beginning of the period |
|
|
664,3 |
|
|
649,9 |
|
649,9 |
| |
Share-based payment expense |
|
|
6,9 |
|
|
6,2 |
|
14,4 |
| |
Balance at the end of the period |
|
|
671,2 |
|
|
656,1 |
|
664,3 |
| |
|
|
|
|
|
|
|
|
|
| |
Fair value adjustment reserve* |
|
|
|
|
|
|
|
|
| |
Balance at the beginning of the period |
|
|
621,1 |
|
|
— |
|
— |
| |
Arising on fair valuation of financial instruments |
7 |
|
— |
|
|
591,7 |
|
660,3 |
| |
Deferred taxation on fair value gain |
|
|
— |
|
|
(39,3) |
|
(39,2) |
| |
Balance at the end of the period |
|
|
621,1 |
|
|
552,4 |
|
621,1 |
| |
|
|
|
|
|
|
|
|
|
| |
Equity transaction with BEE partner |
|
|
|
|
|
|
|
|
| |
Balance at the beginning of the period |
|
|
(35,3) |
|
|
— |
|
— |
| |
Purchase of a portion of BEE partner’s interest in a subsidiary not previously recognised as a minority |
9 |
|
— |
|
|
— |
|
(35,3) |
| |
Balance at the end of the period |
|
|
(35,3) |
|
|
— |
|
(35,3) |
| |
|
|
|
|
|
|
|
|
|
| |
Treasury shares |
|
|
(276,1) |
|
|
(276,1) |
|
(276,1) |
| |
Non-distributable reserves |
|
|
|
|
|
|
|
|
| |
Balance at the beginning of the period |
|
|
4,1 |
|
|
7,3 |
|
7,3 |
| |
Translation reserve |
|
|
1,3 |
|
|
(1,3) |
|
0,7 |
| |
Reunert’s share of previously equity accounted actuarially valued surplus of medical aid provision** |
|
|
— |
|
|
(3,9) |
|
(3,9) |
| |
Balance at the end of the period |
|
|
5,4 |
|
|
2,1 |
|
4,1 |
| |
|
|
|
|
|
|
|
|
|
| |
Retained earnings |
|
|
|
|
|
|
|
|
| |
Balance at the beginning of the period |
|
|
2 590,4 |
|
|
1 997,1 |
|
1 997,1 |
| |
Profit for the period |
|
|
416,6 |
|
|
526,3 |
|
1 156,6 |
| |
Reunert’s share of previously equity accounted valued surplus of medical aid provision transferred from non- distributable reserves** |
|
|
— |
|
|
3,9 |
|
3,9 |
| |
Cash dividends declared and paid |
|
|
(430,2) |
|
|
(428,1) |
|
(567,2) |
| |
Balance at the end of the period |
|
|
2 576,8 |
|
|
2 099,2 |
|
2 590,4 |
| |
Equity attributable to equity holders of
Reunert Limited |
|
|
3 673,1 |
|
|
3 125,7 |
|
3 675,4 |
| |
Minority interest |
|
|
|
|
|
|
|
|
| |
Balance at the beginning of the period |
|
|
20,7 |
|
|
14,4 |
|
14,4 |
| |
Profit for the period |
|
|
2,8 |
|
|
2,7 |
|
7,1 |
| |
Dividends declared and paid |
|
|
(4,0) |
|
|
(1,8) |
|
(1,8) |
| |
Minority interest introduced |
|
|
— |
|
|
1,0 |
|
1,0 |
| |
Balance at the end of the period |
|
|
19,5 |
|
|
16,3 |
|
20,7 |
| |
Total equity at end of the period |
|
|
3 692,6 |
|
|
3 142,0 |
|
3 696,1 |
| |
* |
This reserve relates to fair value adjustments on financial assets designated as “available-for-sale”
financial assets in terms of IAS 39. |
| |
** |
Since Reunert's investment in NSN is no longer equity-accounted this reserve has been transferred
to retained earnings. |
|
|
